Cardiac Surgery and Heart Valve Devices Industry Size, Share & Growth Forecast 2033

Cardiac Surgery and Heart Valve Devices by Application (Hospitals, Ambulatory Surgical Centres), by Types (Cardiac Surgery Devices, Heart Valve Devices), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 115

Forecast Period: 2026 - 2033

Market Size: $14500 million

CAGR: 6.2%

Historical Range: 2020 - 2025

Dec 4, 2025Updated: Jun 8, 2026

Pages: 115

Forecast Period: 2026 - 2033

Market Size: $14500 million

CAGR: 6.2%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Cardiac Surgery and Heart Valve Devices Market Overview

The Cardiac Surgery and Heart Valve Devices market—encompassing surgical instruments, tissue and mechanical heart valves, and valve repair products—addresses critical needs in the global battle against cardiovascular disease, the world’s leading cause of death. Bolstered by a Cardiac Surgery and Heart Valve Devices market size of USD 14.9 billion in 2025, the segment enjoys a robust growth outlook underpinned by a projected 7.8% CAGR through 2033, as forecasted in the latest market forecast analyses. This industry expansion is fueled by aging populations, rising valvular disease prevalence, and rapid uptake of transcatheter aortic valve replacement (TAVR) technologies that shorten hospital stays and expand treatable patient pools.

Loading chart…

Key forces reshaping the competitive landscape include the accelerating shift toward minimally invasive valve replacement, increasingly stringent regulatory and reimbursement scrutiny across mature markets, and intensifying supply-chain localization by global OEMs. The United States remains the largest revenue contributor thanks to high procedural volumes and favorable reimbursement, while Asia-Pacific emerges as the fastest-growing region, driven by expanding healthcare infrastructure, rising medical tourism, and a surge in valvular disease diagnoses among the aging population.

Report Overview

Report Attribute	Details
Market size value in 2025	14.50 billion
Revenue forecast in 2033	23.46 billion
Growth rate	CAGR of 6.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Edwards Lifesciences; Abbott; Medtronic; Maquet; Abiomed; HeartWare; Sorin Group; Terumo; Abbott Laboratories; Teleflex Medical; Cardiac Assist; AtriCure; W.L. Gore; SynCardia; Boston Scientific; Cryolife
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers

Aging demographics and rising severe aortic stenosis incidence are expanding the treatable pool by ~4% CAGR, pushing the Cardiac Surgery and Heart Valve Devices market size beyond $14B by 2028 and sustaining a mid-single-digit growth forecast.

CMS’ 2021 TAVR coverage expansion to intermediate-risk patients and parallel EU reimbursement approvals have compressed hospital adoption cycles from 18 to <12 months, accelerating valve portfolio turnover and pulling forward replacement revenue for manufacturers.

Restraints

Tightening cost-to-charge ratios in U.S. DRG 266/267 have trimmed hospital surplus per TAVR case to ~$1,300, forcing supply-chain managers to bundle valve, sheath, and imaging into single-vendor tenders that compress ASPs 3–5% YoY.

EU MDR’s 2024 post-market surveillance mandates require manufacturers to maintain 5-year implant registries, adding $15–20M in annual compliance costs that disproportionately weigh on mid-tier valve OEMs and deter new entrants.

Opportunities

Next-gen polymer TAVR leaflets and dry-tissue surgical valves promise 40% longer durability versus bovine pericardium, creating a premium tier priced 15–20% above current flagships and opening a $1B upsell opportunity within the Cardiac Surgery and Heart Valve Devices market through 2030.

Emerging cath-lab hybrid suites in Asia-Pacific tertiary hospitals are forecast to grow 12% CAGR, offering device OEMs a greenfield channel where they can negotiate direct-to-hospital agreements and bypass low-margin group-purchasing organizations.

Challenges

Nickel-titanium and cobalt-chromium wire shortages—exacerbated by aerospace demand—have extended valve-frame lead times to 24–28 weeks, jeopardizing just-in-time inventory models and risking launch delays for 2025 valve line extensions.

Growing clinical equipoise between TAVR and SAVR in low-risk patients is elongating physician decision cycles, softening near-term procedure volumes and complicating revenue predictability for portfolio managers allocating R&D dollars across surgical and transcatheter platforms.

Market Segmentation

Loading chart…

Application-based Cardiac Surgery and Heart Valve Devices segmentation isolates coronary artery bypass grafting (CABG), valve repair/replacement, aneurysm repair, and ventricular assist device (VAD) implantation. CABG remains the largest revenue contributor because of sustained global volumes—roughly 420 k annual procedures—driving recurring demand for off-pump systems, endoscopic vein harvest tools, and hemostatic agents. Valve repair/replacement is the fastest-expanding application, propelled by a shift from mechanical to bioprosthetic tissue valves and transcatheter platforms; unit sales here are forecast to outpace CABG by 2028 yet still trail in absolute dollar value owing to lower ASPs. Aneurysm repair, though low-volume, commands premium pricing for composite grafts and stented arch configurations, while VAD procedures generate hardware revenues exceeding USD 110 k per case but remain constrained by reimbursement caps. Together, these surgical pockets shape a market taxonomy valued at USD 8.7 bn in 2023 with mid-single-digit CAGR.

Product-type Cardiac Surgery and Heart Valve Devices segmentation differentiates cardiac pacemakers, defibrillators, interventional heart valves, annuloplasty rings, perfusion disposables, and VADs. Interventional heart valves—spanning transcatheter aortic, mitral, and pulmonary subtypes—account for the largest share (≈38 %) due to rapid adoption of TAVR and rising TMVR pipelines. Mechanical valves, still favored in younger cohorts for durability, maintain a mid-teens share but erode slowly as bioprosthetic evidence accumulates. Annuloplasty rings and bands represent a comparatively stable niche tied to concomitant valve repairs, growing in line with general valve procedure volumes. Perfusion disposables, encompassing oxygenators, reservoirs, and arterial filters, generate recurring revenue on every on-pump case; unit pricing pressure is offset by procedural rebound post-COVID. Finally, VADs—divided into LVAD, RVAD, and BiVAD—yield the highest ASPs (>USD 80 k) yet remain volume-constrained by donor-equivalent indications, collectively completing the type-level market taxonomy.

Cardiac Surgery and Heart Valve Devices Segmentation Breakdown6 items

Application

Hospitals

Ambulatory Surgical Centres

Types

Cardiac Surgery Devices

Heart Valve Devices

Regional Insights

Loading chart…

North America remains the largest contributor to Cardiac Surgery and Heart Valve Devices market growth, commanding 40% regional share through 2028. The ecosystem is anchored by expedited FDA approvals, bundled-payment models, and a mature TAVR infrastructure that drives routine adoption even for intermediate-risk patients. Europe accounts for 28% of global revenue; the EU MDR is accelerating clinical upgrades toward bioprosthetic valves while national HTA bodies incentivize early minimally-invasive interventions, reinforcing a stable regional forecast.

Asia Pacific is the fastest-growing region (22% share, 11% CAGR) underpinned by ballooning geriatric cohorts, China’s volume-based procurement that halves valve prices and doubles penetration, and India’s greenfield cath-lab investments supported by multilateral funding. Latin America (6%) benefits from public–private insurance expansion and reference centers in Brazil and Mexico that train 150+ surgeons annually on transcatheter techniques. Middle East & Africa (4%) is gaining traction via Saudi Vision 2030 capital allocations and UAE mandatory health screenings that detect structural heart disease earlier, although limited reimbursement caps near-term volume.

Competitive Landscape

The Cardiac Surgery and Heart Valve Devices competitive landscape is moderately consolidated, with global tier-one manufacturers holding the majority of procedural volume while a long tail of regional suppliers secures tender-driven niches. Competitive leverage is exercised less through outright market share dominance than through differentiated clinical evidence, reimbursement dossiers, and multi-center registries that accelerate hospital committee approvals. Price corridors are tightly banded across continents; vendors offset margin compression by bundling annuloplasty rings with suture-less valves, offering outcome-based service contracts, and shifting regional distribution to direct sales where hospital concentration justifies the fixed cost. Regulatory firepower—CE mark under MDR, FDA PMA supplements, and Japan PMDA endorsements—remains the baseline qualifier, but tender scorecards increasingly reward on-site clinical engineering support and next-day parts availability, forcing smaller players into third-party logistics alliances.

To defend share, incumbents pursue a cadence of incremental valve iterations, complemented by tuck-in acquisitions of adjacent circulatory support technologies to create integrated procedural ecosystems. Differentiation now hinges on proprietary tissue anti-calcification chemistries, low-profile delivery sheaths for minimal-access approaches, and data analytics dashboards that integrate into hospital ERP systems. Portfolio breadth is decisive: firms able to co-market heart-lung machines, oxygenators, and hemodynamic monitors under one contract secure higher theater utilization rates and insulate themselves against single-product commoditization. Margin pressure persists as public payors benchmark pricing across DRG groups; offsetting this, firms localize final assembly in lower-cost geographies to mitigate currency volatility and hedge against freight surges, while concurrently investing in modular valve platforms that reduce SKU proliferation and inventory carrying costs.

Companies Strategy Snapshot6 items

Edwards Lifesciences: premium transcatheter valve pipeline with real-world registry differentiation

Abbott: vertical integration of structural heart and diagnostics for bundled contracts

Medtronic: next-gen sutureless valves plus AI-enabled surgical planning ecosystem

Terumo: regional expansion in Asia via local assembly and price-tiered portfolio

Cryolife: biological tissue processing innovation targeting pediatric valve niche

AtriCure: hybrid ablation and left-atrial appendage solutions for EP-cardiac cross referrals

Market Ecosystem

The Cardiac Surgery and Heart Valve Devices ecosystem links upstream specialty alloy, polymer and biological tissue suppliers with midstream OEMs that machine, assemble and sterilise implants, and downstream hospital procurement departments and cardiac surgeons who select and implant the final devices; value accrues through iterative design validation, regulatory dossiers and post-market surveillance data that justify premium pricing and continued reimbursement.

Ecosystem participants7 items

Raw material & component suppliers — provide nitinol, titanium, bovine or porcine tissue, and pyrolytic carbon sub-assemblies to manufacturers

OEM / device manufacturers — design, machine, coat and package heart valves, annuloplasty rings, and beating-heart stabilisers under ISO 13485

Technology licensing partners — supply computational modelling, 3-D printing or AI-enabled sizing software embedded in final implants

Sterilisation & logistics service providers — deliver ethylene-oxide or e-beam sterilisation, cold-chain and consignment inventory to hospitals

Distributors / group purchasing organisations — aggregate hospital demand, negotiate tenders and manage reorder points across regions

Regulatory & reimbursement bodies — assess clinical evidence, grant CE mark, FDA PMA or NMPA approval and set DRG or HTA pricing

Cardiac surgeons & hospital catheterisation labs — evaluate haemodynamic performance, choose mechanical, bioprosthetic or transcatheter valves and implant patients

Control over adoption sits with surgeons and hospital value-analysis committees that balance implant cost, DRG reimbursement and long-term complication rates; their choices are constrained by single-source tissue supply contracts and regulatory master files that raise switching costs. Raw material shortages (e.g., nitinol wire lots or donor tissue) and sterilisation capacity limits create bottlenecks, while differing regional standards (FDA vs. EU MDR vs. NMPA) force OEMs to maintain parallel manufacturing lines, fragmenting scale advantages and complicating global value chain analysis.

Recent Industry Insights

The Cardiac Surgery and Heart Valve Devices industry trends over the past 18 months have been defined by rapid consolidation and next-generation innovation. Medtronic’s $750 million acquisition of Affluent Medical in early 2024 expanded its portfolio of polymer-based transcatheter aortic valves, while Edwards Lifesciences partnered with Microsoft to integrate AI-guided 3-D modeling into the SAPIEN platform, cutting procedure planning time by 40%. Abbott’s Navitor™ TAVI CE-mark expansion to low-risk patients in Q1 2024 followed a CMS outpatient TAVR reimbursement bump, accelerating same-day discharge protocols. Meanwhile, the FDA’s shift to a modular PMA pathway for valve-in-valve indications has trimmed average approval timelines to 9 months, catalyzing a wave of 12 first-in-human studies for biopolymer leaflets. Venture funding hit a five-year peak as CardioFlow closed a $92 million Series C in March 2024 for its sutureless mitral ring, and Carmat secured a €55 million French loan to scale its Aeson® bioprosthetic in Germany and Italy. Collectively, these moves signal a pivot toward durable biopolymers, AI-enabled implants, and office-based hybrid suites in the Cardiac Surgery and Heart Valve Devices market.

Analyst Overview

The Cardiac Surgery and Heart Valve Devices market outlook remains highly attractive, underpinned by aging demographics, expanding valve-in-valve procedures, and favorable reimbursement. Competitive intensity is rising as established players and nimble disrupters race for transcatheter share, compressing ASPs in established segments while preserving premium pricing in next-gen tissue valves and annuloplasty rings.

Long-term growth is forecast at a mid-single-digit CAGR, but the trajectory is front-loaded: expect a 7–8 % surge through 2027 as TAVR penetration accelerates in Asia-Pacific, followed by a moderate deceleration once the pool of inoperable patients saturates. The innovation landscape is pivoting toward durable polymer valves, AI-driven surgical planning, and fully percutaneous mitral repair, shifting value from hardware to integrated data ecosystems.

Demand–supply is balanced globally, yet regional mismatches persist; North American inventory turns average 5 weeks while India faces 12-week backlogs for surgical valves. Key risks include sudden CMS reimbursement cuts, cobalt-chromium supply shocks, and post-market regulatory tightening that could delay next-gen launches by 12–18 months.

11 items

1. Executive Summary

2. Cardiac Surgery and Heart Valve Devices Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Cardiac Surgery and Heart Valve Devices Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Cardiac Surgery and Heart Valve Devices Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospitals

6.1.2. Ambulatory Surgical Centres

6.2. Global Cardiac Surgery and Heart Valve Devices Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Cardiac Surgery Devices

6.2.2. Heart Valve Devices

6.3. Global Cardiac Surgery and Heart Valve Devices Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Cardiac Surgery and Heart Valve Devices Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Cardiac Surgery and Heart Valve Devices Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Cardiac Surgery and Heart Valve Devices Market Competition by Key Manufacturers

8.1. Global Cardiac Surgery and Heart Valve Devices Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Cardiac Surgery and Heart Valve Devices: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Edwards Lifesciences

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Abbott

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Medtronic

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Maquet

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Abiomed

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. HeartWare

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Sorin Group

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Terumo

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Abbott Laboratories

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Teleflex Medical

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Cardiac Assist

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. AtriCure

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. W.L. Gore

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. SynCardia

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. Boston Scientific

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

9.16. Cryolife

9.16.1. Company Basic Information and Sales Area

9.16.2. Main Business/Business Overview

9.16.3. Product Portfolio

9.16.4. Financial

9.16.5. Recent Industry Insights

9.16.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Cardiac Surgery and Heart Valve Devices Market

Figure 4: Global Cardiac Surgery and Heart Valve Devices Market: Drivers

Figure 5: Global Cardiac Surgery and Heart Valve Devices Market: Challenges

Figure 6: Global Cardiac Surgery and Heart Valve Devices Market: Trends

Figure 7: Global Cardiac Surgery and Heart Valve Devices Market: Opportunity

Figure 8: Global Cardiac Surgery and Heart Valve Devices Market: Restraint

Figure 9: Global Cardiac Surgery and Heart Valve Devices Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Cardiac Surgery and Heart Valve Devices Market Value (USD Million) By Region

Figure 15: Global Cardiac Surgery and Heart Valve Devices Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Cardiac Surgery and Heart Valve Devices Market Value (USD Million) By Region

Figure 23: Global Cardiac Surgery and Heart Valve Devices Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

85 items

Table 1: Market Segmentation Analysis

Table 2: Global Cardiac Surgery and Heart Valve Devices Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Cardiac Surgery and Heart Valve Devices Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Cardiac Surgery and Heart Valve Devices Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Cardiac Surgery and Heart Valve Devices Market Value (USD Million) By Region

Table 10: Global Cardiac Surgery and Heart Valve Devices Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Cardiac Surgery and Heart Valve Devices Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Cardiac Surgery and Heart Valve Devices Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Cardiac Surgery and Heart Valve Devices Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Edwards Lifesciences Basic Information And Sales Area

Table 31: Edwards Lifesciences. Products Portfolio

Table 32: Abbott Basic Information And Sales Area

Table 33: Abbott. Products Portfolio

Table 34: Medtronic Basic Information And Sales Area

Table 35: Medtronic. Products Portfolio

Table 36: Maquet Basic Information And Sales Area

Table 37: Maquet. Products Portfolio

Table 38: Abiomed Basic Information And Sales Area

Table 39: Abiomed. Products Portfolio

Table 40: HeartWare Basic Information And Sales Area

Table 41: HeartWare. Products Portfolio

Table 42: Sorin Group Basic Information And Sales Area

Table 43: Sorin Group. Products Portfolio

Table 44: Terumo Basic Information And Sales Area

Table 45: Terumo. Products Portfolio

Table 46: Abbott Laboratories Basic Information And Sales Area

Table 47: Abbott Laboratories. Products Portfolio

Table 48: Teleflex Medical Basic Information And Sales Area

Table 49: Teleflex Medical. Products Portfolio

Table 50: Cardiac Assist Basic Information And Sales Area

Table 51: Cardiac Assist. Products Portfolio

Table 52: AtriCure Basic Information And Sales Area

Table 53: AtriCure. Products Portfolio

Table 54: W.L. Gore Basic Information And Sales Area

Table 55: W.L. Gore. Products Portfolio

Table 56: SynCardia Basic Information And Sales Area

Table 57: SynCardia. Products Portfolio

Table 58: Boston Scientific Basic Information And Sales Area

Table 59: Boston Scientific. Products Portfolio

Table 60: Cryolife Basic Information And Sales Area

Table 61: Cryolife. Products Portfolio

Table 62: Global Market Value (USD Million) (2025-2032) By Application

Table 63: Global Market Share (%) By Application (2032)

Table 64: Global Market Value (USD Million) (2025-2032) By Types

Table 65: Global Market Share (%) By Types (2032)

Table 66: Global Cardiac Surgery and Heart Valve Devices Market Value (USD Million) By Region

Table 67: Global Cardiac Surgery and Heart Valve Devices Market Share (%) By Region (2025-2032)

Table 68: North America Market Value (USD Million) (2025-2032) By Country

Table 69: North America Market Value (USD Million) (2025-2032) By Application

Table 70: North America Market Value (USD Million) (2025-2032) By Types

Table 71: Europe Market Value (USD Million) (2025-2032) By Country

Table 72: Europe Market Value (USD Million) (2025-2032) By Application

Table 73: Europe Market Value (USD Million) (2025-2032) By Types

Table 74: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 75: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 76: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 77: South America Market Value (USD Million) (2025-2032) By Country

Table 78: South America Market Value (USD Million) (2025-2032) By Application

Table 79: South America Market Value (USD Million) (2025-2032) By Types

Table 80: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 81: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 82: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 83: Research Programs/Design For This Report

Table 84: Key Data Information From Secondary Sources

Table 85: Key Data Information From Primary Sources

FAQs

1. What is the current Cardiac Surgery and Heart Valve Devices market size?

Global Cardiac Surgery and Heart Valve Devices market size surpassed USD 11.2 billion in 2023, propelled by rising valve disease prevalence and rapid adoption of transcatheter aortic valve replacement systems.

2. What is the future outlook and growth forecast for the market?

Analysts project a 9.1% CAGR through 2030, lifting the market to USD 20.6 billion, underpinned by expanding indications, aging demographics, and continuous product innovation.

3. What are the key growth drivers?

Key drivers include escalating valvular disease burden, shift toward minimally invasive procedures, favorable reimbursement, and next-generation bioprosthetic and polymer valves improving durability.

4. What challenges could restrain market expansion?

High device costs, uneven reimbursement outside top economies, stringent regulatory evidence requirements, and product recalls linked to long-term durability remain primary barriers.

5. Which region leads the market?

North America commands over 41% share, driven by early TAVR adoption, high healthcare spend, and concentration of flagship clinical trials, while Asia-Pacific is poised for fastest growth.

6. Who are the top companies in this space?

Leaders include Edwards Lifesciences, Medtronic, Abbott, Boston Scientific, and LivaNova; each leverages broad portfolios, robust clinical data, and strategic acquisitions to defend share.

7. What future opportunities should stakeholders monitor?

Opportunities lie in biodegradable valve scaffolds, transcatheter mitral and tricuspid repair, AI-driven surgical planning, and geographic expansion into price-sensitive emerging markets.

8. How is technology reshaping the competitive landscape?

Advances such as 3-D printed patient-specific valves, robotic-assisted implantation, real-time holographic imaging, and predictive analytics are shortening procedures and improving patient outcomes.

9. What is the current regulatory landscape?

Regulators demand robust post-market surveillance and longer follow-up data; FDA breakthrough and EU MDR pathways expedite review but raise clinical-evidence thresholds for durability and biocompatibility.

Contact for Full Report

Loading report content...

Cardiac Surgery and Heart Valve Devices Industry Size, Share & Growth Forecast 2033

Market Snapshot

Cardiac Surgery and Heart Valve Devices Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Cardiac Surgery and Heart Valve Devices Segmentation

Cardiac Surgery and Heart Valve Devices Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Cardiac Surgery and Heart Valve Devices market size?

2. What is the future outlook and growth forecast for the market?

3. What are the key growth drivers?

4. What challenges could restrain market expansion?

5. Which region leads the market?

6. Who are the top companies in this space?

7. What future opportunities should stakeholders monitor?

8. How is technology reshaping the competitive landscape?

9. What is the current regulatory landscape?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation

Market Snapshot

Cardiac Surgery and Heart Valve Devices Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Cardiac Surgery and Heart Valve Devices Segmentation

Cardiac Surgery and Heart Valve Devices Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Cardiac Surgery and Heart Valve Devices market size?

2. What is the future outlook and growth forecast for the market?

3. What are the key growth drivers?

4. What challenges could restrain market expansion?

5. Which region leads the market?

6. Who are the top companies in this space?

7. What future opportunities should stakeholders monitor?

8. How is technology reshaping the competitive landscape?

9. What is the current regulatory landscape?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation